250: Serum adiponectin and long term mortality in coronary heart disease patients and control patients

Abstract

We investigated in 715 men aged 45-74 with stable coronary artery disease (CAD) and 782 controls whether serum adiponectin was associated with long-term total and cardiovascular diseases (CVD) mortality, considering varying degrees of CAD severity. Adiponectin was lower in patients (5.6±0.2 μg/mL) than in controls (7.1±0.2 μg/mL), (p<0.001) but became similar after multivariate adjustment (6.1±0.3 μg/mL) and (6.5±0.3 μg/mL) respectively (p=0.17). During a median follow-up of 8.1 years, survival rates among CAD patients in increasing quartiles of serum adiponectin values were 87.5%, 85.6%, 76.4% and 67.6%, respectively (p<0.001 by log-rank test). Survival rates in controls with adiponectin <9.1 μg/mL and ≥9.1 μg/mL (third quartile) were 95.3% and 91.0% respectively (p=0.035 by log-rank test). Adiponectin concentration above the highest quartile was associated with an increased risk of all-cause and cardiovascular mortality in CAD patients (p=0.001 and p=0.001 respectively) and in controls (p=0.03 and p=0.01 respectively). An increase of 1 μg/mL of adiponectin was associated with an increased risk of total mortality of 8.0% (HR= 1.08 [95% CI 1.05-1.11], p<0.001) in the whole population, combining both CAD patients and controls. The associations between high adiponectin and total or cardiovascular mortality remained significant after multivariate adjustment. High serum adiponectin is a powerful predictor of mortality particularly from CVD. This prognostic value remains significant whatever the severity of the CAD and is not different among people with and without CAD.